CareDx, Inc. (CDNA)
66.68
+1.98
(+3.07%)
USD |
NASDAQ |
Oct 15, 16:00
66.76
+0.08
(+0.13%)
After-Hours: 20:00
CareDx Research and Development Expense (Quarterly) : 22.38M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.38M |
| March 31, 2026 | 21.42M |
| December 31, 2025 | 19.31M |
| September 30, 2025 | 16.77M |
| June 30, 2025 | 16.83M |
| March 31, 2025 | 18.52M |
| December 31, 2024 | 16.45M |
| September 30, 2024 | 17.49M |
| June 30, 2024 | 19.69M |
| March 31, 2024 | 18.71M |
| December 31, 2023 | 18.28M |
| September 30, 2023 | 19.00M |
| June 30, 2023 | 20.23M |
| March 31, 2023 | 24.36M |
| December 31, 2022 | 23.57M |
| September 30, 2022 | 22.31M |
| June 30, 2022 | 22.63M |
| March 31, 2022 | 21.88M |
| December 31, 2021 | 22.05M |
| September 30, 2021 | 19.44M |
| June 30, 2021 | 19.04M |
| March 31, 2021 | 16.00M |
| December 31, 2020 | 13.32M |
| September 30, 2020 | 12.47M |
| June 30, 2020 | 13.13M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.01M |
| December 31, 2019 | 8.946M |
| September 30, 2019 | 8.521M |
| June 30, 2019 | 7.63M |
| March 31, 2019 | 5.614M |
| December 31, 2018 | 3.782M |
| September 30, 2018 | 3.868M |
| June 30, 2018 | 3.496M |
| March 31, 2018 | 3.368M |
| December 31, 2017 | 3.028M |
| September 30, 2017 | 2.959M |
| June 30, 2017 | 3.118M |
| March 31, 2017 | 3.283M |
| December 31, 2016 | 3.154M |
| September 30, 2016 | 2.93M |
| June 30, 2016 | 3.143M |
| March 31, 2016 | 3.159M |
| December 31, 2015 | 2.704M |
| September 30, 2015 | 2.698M |
| June 30, 2015 | 2.51M |
| March 31, 2015 | 1.421M |
| December 31, 2014 | 1.298M |
| September 30, 2014 | 1.036M |
| June 30, 2014 | 0.792M |
| March 31, 2014 | 0.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Natera, Inc. | 228.07M |
| Caris Life Sciences, Inc. | 32.36M |
| Myriad Genetics, Inc. | 25.00M |
| BioRestorative Therapies, Inc. | 1.926M |
| Exagen, Inc. | 1.426M |